I-131 25/30 MCI (DOSE FOR THERAPY)

About I-131 25/30 mCi Therapy

I-131 25/30 mCi Therapy is a nuclear medicine treatment that uses radioactive iodine-131 (I-131) for selected thyroid conditions when prescribed by a qualified specialist. Radioactive iodine is taken up by iodine-avid thyroid tissue, allowing targeted therapeutic radiation to the relevant cells.

The prescribed I-131 activity is determined by the treating specialist based on the patient's diagnosis, clinical condition, previous treatment and treatment plan. The 25/30 mCi activity listed for this service represents the available prescribed therapy dose range.

What Is I-131 Therapy Used For?

Radioactive iodine therapy may be used for selected thyroid conditions, including certain cases of hyperthyroidism and differentiated thyroid cancer, depending on the clinical indication.

The appropriate radioactive iodine activity and treatment approach vary between patients and should be determined by the treating nuclear medicine physician or endocrinologist.

Why Is I-131 Therapy Performed?

I-131 therapy is performed when targeted radioactive iodine treatment is clinically appropriate. Because iodine-avid thyroid tissue naturally takes up iodine, I-131 can deliver therapeutic radiation to the targeted tissue.

The treatment may be recommended to reduce excessive thyroid activity or, in selected thyroid cancer cases, to treat remaining iodine-avid thyroid tissue after appropriate clinical evaluation.

How Is I-131 25/30 mCi Therapy Performed?

The prescribed I-131 activity is administered under the supervision of the nuclear medicine team. Depending on the treatment protocol, radioactive iodine may be administered orally in an appropriate formulation.

After administration, I-131 is taken up by iodine-avid tissue and delivers therapeutic radiation over time. The patient receives specific radiation-safety and post-treatment instructions from the nuclear medicine team.

Preparation for I-131 Therapy

Preparation requirements vary according to the treatment indication and prescribed protocol. Patients may receive specific instructions regarding diet, medications and iodine exposure before therapy.

Patients should inform the nuclear medicine team about pregnancy or possible pregnancy, breastfeeding, current medications, previous thyroid treatment and other relevant medical conditions before receiving I-131 therapy.

Pregnancy must be excluded when required by the treatment protocol, and breastfeeding considerations should be discussed with the treating specialist before therapy.

Radiation Safety After I-131 Therapy

Because I-131 emits radiation after administration, patients may need to follow temporary radiation-safety precautions after treatment. Instructions may include maintaining appropriate distance from others, hygiene precautions and specific guidance regarding contact with children or pregnant individuals.

The duration and extent of precautions depend on the administered activity, treatment indication and individual circumstances. Patients should follow the exact instructions provided by the nuclear medicine team.

Benefits of I-131 Therapy

I-131 therapy provides targeted radioactive treatment to iodine-avid thyroid tissue. It is an established nuclear medicine treatment used for selected thyroid conditions under appropriate specialist supervision.

The treatment response varies according to the underlying thyroid condition, administered activity and individual patient factors.

Understanding Follow-Up After I-131 Therapy

Follow-up after radioactive iodine therapy depends on the treatment indication. Patients may require thyroid function tests, clinical assessment, imaging or additional nuclear medicine evaluation according to the treating specialist's plan.

The response to therapy should be assessed using appropriate clinical and laboratory investigations. Patients should attend all recommended follow-up appointments.

I-131 25/30 mCi Therapy in Hyderabad

Focus Diagnostics provides nuclear medicine therapy services in Hyderabad for appropriate clinical indications. Patients can consult their treating endocrinologist, oncologist or nuclear medicine physician regarding eligibility, preparation, treatment protocol, radiation-safety instructions and follow-up.